Could a new rescue inhaler strategy reduce severe asthma attacks in mild cases?
This week's episode covers the effectiveness of a fixed-dose albuterol-budesonide combination for asthma, new findings on Nerodomelast for progressive pulmonary fibrosis, the FDA’s endorsement of a new COVID-19 vaccine targeting the JN.1 lineage, and insights into extended-phase anticoagulation for pediatric venous thromboembolism.
--------
6:32
Could ending PEPFAR lead to 1 million new pediatric HIV cases by 2030?
A Lancet study warns of consequences for HIV prevention if PEPFAR loses funding, potentially millions of new pediatric HIV cases and increased AIDS-related deaths. Medicare Part D is highlighted, with research linking subsidy loss to higher mortality rates. A report from BMJ notes a 3.1% decline in U.S. drug overdose deaths, signaling a possible peak in the fentanyl crisis.
--------
4:52
Revisiting Anemia Response in Myelofibrosis: Revised International Working Group Criteria
Drs. Pemmaraju and Bose discuss the revised International Working Group criteria for anemia response in patients with myelofibrosis, outlining new definitions for transfusion status, gender-specific hemoglobin thresholds, and benchmarks for major and minor responses.
--------
7:21
Leukemic Transformation in Myelofibrosis: Risks, Realities, and Evolving Strategies
Drs. Bose and Pemmaraju discuss leukemic transformation in patients with myelofibrosis, reviewing its incidence, as well as risk factors, treatment, and prognosis.
--------
7:34
Understanding Secondary Myelofibrosis: Diagnosis, Treatment, and Prognosis
Drs. Bose and Pemmaraju review secondary myelofibrosis arising from polycythemia vera or essential thrombocythemia and how it differs from primary myelofibrosis that develops de novo.
The Medical News Podcast by PeerDirect delivers news and interviews with clinical thought leaders and researchers to keep you informed of the latest breakthroughs, guidelines, and insights in your specialty. Designed for clinicians with stories selected by the PeerDirect editorial board. Visit us at peerdirect.com to sign-up for our newsletter.